Lakefront Biotherapeutics NV (LKFT)

Currency in EUR
23.02
+0.12(+0.52%)
Closed·
LKFT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
22.7823.18
52 wk Range
22.6232.74
Key Statistics
Prev. Close
22.9
Open
22.94
Day's Range
22.78-23.18
52 wk Range
22.62-32.74
Volume
80.21K
Average Volume (3m)
82.73K
1-Year Change
-6.6504%
Book Value / Share
49.37
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LKFT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
31.74
Upside
+37.89%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell

Analyst Ratings

1 Buy
5 Hold
2 Sell
Ratings:
8 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 31.74
(+37.89% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Sell22.00-4.43%-MaintainJan 07, 2026
Bernstein SocGen Group
Hold27.90+21.20%-New CoverageNov 25, 2025
Deutsche Bank
Sell19.00-17.46%22.00DowngradeAug 05, 2025

Earnings

Latest Release
May 06, 2026
EPS / Forecast
0,21 / -0,82
Revenue / Forecast
6,48M / 29,02M
EPS Revisions
Last 90 days

LKFT Income Statement

Compare LKFT to Peers and Sector

Metrics to compare
LKFT
Peers
Sector
Relationship
P/E Ratio
3.1x−0.2x−0.5x
PEG Ratio
0.010.070.00
Price/Book
0.5x1.8x2.6x
Price / LTM Sales
1.4x5.2x3.2x
Upside (Analyst Target)
31.0%87.1%55.3%
Fair Value Upside
Unlock11.7%9.7%Unlock

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
7,63M11,58%174,73M
Other Institutional Investors
50,13M76,08%1,15B
Public Companies & Retail Investors
8,14M12,35%186,30M
Total
65,9M100,00%1,51B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Gilead Sciences, Inc.25,35%16 707 477382 601
Ecor1 Capital Fund Qualified, L.P.12,43%8 192 077187 599

FAQ

What Is the Lakefront (LKFT) Stock Price Today?

The Lakefront stock price today is 23,02 EUR.

What Stock Exchange Does Lakefront Trade On?

Lakefront is listed and trades on the Amsterdam Stock Exchange.

What Is the Stock Symbol for Lakefront?

The stock symbol for Lakefront is "LKFT."

What Is the Lakefront Market Cap?

As of today, Lakefront market cap is 1,52B EUR.

What Is Lakefront's Earnings Per Share (TTM)?

The Lakefront EPS (TTM) is 7,40.

When Is the Next Lakefront Earnings Date?

Lakefront will release its next earnings report on Aug 10, 2026.

From a Technical Analysis Perspective, Is LKFT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Lakefront Stock Split?

Lakefront has split 0 times.

How Many Employees Does Lakefront Have?

Lakefront has 704 employees.

What is the current trading status of Lakefront (LKFT)?

As of May 19, 2026, Lakefront (LKFT) is trading at a price of 23,02 EUR, with a previous close of 22,90 EUR. The stock has fluctuated within a day range of 22,78 EUR to 23,18 EUR, while its 52-week range spans from 22,62 EUR to 32,74 EUR.

What Is Lakefront (LKFT) Price Target According to Analysts?

The average 12-month price target for Lakefront is 31,74 EUR, with a high estimate of 44.8 EUR and a low estimate of 22 EUR. 1 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Neutral. The stock has an +37,89% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.